METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo targets incurable esophageal cancer
Disease control OngoingThis early-phase study tested a drug called adavosertib combined with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Matched conditions: METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:32 UTC
-
New combo therapy shows promise for tough esophageal cancer
Disease control OngoingThis study tests whether adding the drug cixutumumab to standard chemotherapy (paclitaxel) can help people with advanced esophageal or stomach-junction cancer live longer without their cancer growing. About 94 adults whose cancer has spread and who have already tried one treatmen…
Matched conditions: METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
New drug cocktail shows promise in tough esophageal cancer trial
Disease control OngoingThis study tests whether adding the drug lenvatinib to a standard treatment (pembrolizumab plus chemotherapy) helps people with advanced esophageal cancer live longer. About 864 participants will receive either the new three-drug combo or the standard two-drug combo. The goal is …
Matched conditions: METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 18, 2026 12:02 UTC